Telomerase Activator
Supporting cellular longevity at the telomere level.
Epithalon is a synthetic tetrapeptide researched for its potential to activate telomerase—the enzyme responsible for maintaining and lengthening telomeres. By supporting telomere health, Epithalon is studied for its role in cellular longevity, aging modulation, and overall vitality.
10mg
Standard Dosage
Daily
Typical Frequency
Telomere
Target Mechanism
22+
BHRC Locations
Available Formulation
A research-grade tetrapeptide designed to support telomerase activation and cellular longevity pathways.
Epithalon Tetrapeptide
Ideal For
Individuals seeking evidence-based longevity support, those interested in cellular aging interventions, patients focused on healthspan optimization, and anyone looking to support telomere health and biological age management.
The Science
Epithalon (also known as Epitalon) is a synthetic tetrapeptide derived from epithalamin, a polypeptide produced by the pineal gland. Composed of four amino acids (Ala-Glu-Asp-Gly), Epithalon has been extensively researched for its ability to activate telomerase and influence telomere length.
Telomeres are protective caps at the ends of chromosomes that shorten with each cell division. When telomeres become critically short, cells enter senescence or apoptosis, contributing to aging. Epithalon is studied for its potential to activate telomerase—the enzyme that can rebuild and lengthen telomeres—thereby supporting cellular health and longevity.
At BHRC, we offer pharmaceutical-grade Epithalon as part of our longevity and preventive health protocols for patients seeking cutting-edge, research-backed interventions in aging modulation and healthspan optimization.
Book a Consultation
How It Works
Epithalon works primarily through telomerase activation, supporting cellular longevity by influencing telomere maintenance and circadian rhythm regulation.
Activates telomerase enzyme to potentially lengthen and maintain telomeres—protecting chromosomes from degradation and supporting healthy cellular replication and lifespan.
Influences pineal gland function and melatonin secretion, supporting healthy circadian rhythms, sleep quality, and hormonal balance—all critical for optimal aging and metabolic health.
Influences the expression of genes associated with aging, antioxidant defense, and cellular stress response—promoting resilience and adaptive capacity at the molecular level.
Research Benefits
Supports telomere health and cellular replication capacity, potentially slowing cellular aging and promoting healthy tissue function across organ systems.
Regulates pineal gland function and melatonin secretion, supporting deeper, more restorative sleep and healthy circadian rhythm alignment.
Enhances cellular antioxidant defense systems, protecting against oxidative stress and free radical damage associated with aging.
May support immune system resilience by maintaining healthy immune cell populations and function—studied in older research.
Studied for effects on metabolic regulation, insulin sensitivity, and mitochondrial function in preclinical research.
By supporting cellular health and regeneration, Epithalon may improve skin appearance, tissue repair, and overall physical vitality.
Your Journey
Our medical team guides you through every step—from initial consultation to ongoing optimization.
Meet with our physician to discuss your longevity goals and determine if Epithalon therapy aligns with your health objectives.
Comprehensive evaluation including medical history, biomarker review, and establishment of personalized longevity protocols and goals.
Personalized treatment plan with precise dosing schedule, administration guidance, and integration with complementary longevity interventions.
Regular follow-ups with biomarker tracking, clinical assessments, and protocol review over time.
Safety & Candidacy
Epithalon has been studied mainly in animal research and small human studies, and human safety data remain limited. While not FDA-approved for longevity enhancement, it's used in some supervised wellness protocols focused on healthspan.
10-20 days
Typical treatment cycle duration for Epithalon protocols
Daily
Standard dosing frequency during active treatment cycles
At a glance
Your plan
The BHRC clinical team starts with your goals and the basics that move healthspan the most: sleep, activity, blood pressure, glucose, lipids, smoking and alcohol, and age-appropriate cancer screening. If those are not in place, they come first, and Epithalon waits.
We record markers that can be re-measured and acted on, such as fasting glucose, HbA1c, lipids, inflammatory markers, blood pressure, sleep quality scores and, if you want one, a commercial biological-age or telomere test. We explain up front what those tests can and cannot tell you, and we note the exact test and lab used so that next year's result is comparable.
If you qualify, the plan is a short cycle with a defined start and end date, followed by a long break. Dosing and cycle length are set by the clinical team; nothing is open-ended. You leave with written instructions, a sharps plan, storage guidance for the vial and a list of symptoms that mean you should call before the next dose.
A brief check covers injection sites, sleep changes and anything new. At the end of the cycle the plan pauses on schedule, whether or not you feel a difference.
Markers are repeated at a consistent interval, and the team decides with you whether another cycle next year is worthwhile, or whether your time and budget are better spent elsewhere in the plan.
Timeline
Consultation, preventive-care check and baseline markers. Screening that is overdue is arranged first.
Most people notice little day to day. Some report sleep changes, which fits the pineal and melatonin research, but this is not consistent.
The vial course stops on the planned date. There is no taper and no maintenance dosing between cycles, and any unused peptide is discarded according to the pharmacy label rather than saved for later.
Months of no peptide, with the lifestyle and preventive parts of the plan continuing. This is where most of the measurable change in a longevity plan actually comes from: sleep, training, blood pressure and glucose.
Re-measured markers are compared at the annual review. Single telomere readings vary between labs and tests, so trends matter more than one result.
Compare
| Option | Proposed target | Human evidence | How it fits a plan |
|---|---|---|---|
| Epithalon (this page) | Telomerase and pineal rhythm | Small studies; mostly cell and animal data | Short yearly cycles as an adjunct |
| NAD+ | Cellular NAD levels and energy metabolism | Human studies of precursors, mixed results | Ongoing support; see our NAD+ page |
| MOTS-c | Mitochondrial signalling, insulin sensitivity | Mostly animal data | Metabolic focus; see our MOTS-c page |
| GHK/Epi/MOTS blend | Three pathways in one vial | Each component studied separately | For patients who want a combined protocol |
Is it right for you?
Monitoring
The idea behind Epithalon is that it can switch on telomerase, the enzyme that maintains the ends of chromosomes. That is shown in human cell lines in the laboratory, including a 2025 study reporting telomere lengthening through telomerase or an alternative lengthening mechanism, but no controlled trial has shown that injecting Epithalon changes how people age. Monitoring at BHRC is designed around that gap: we track what can be measured and avoid implying outcomes that have not been demonstrated.
Because telomerase activity is also a feature of many cancers, the BHRC clinical team takes cancer screening seriously before and between cycles. A personal history of cancer, a suspicious finding or an overdue screening test means Epithalon is not started. That is a precaution based on biology, not on a proven risk, and we say so.
If you choose to buy a telomere or biological-age test, the team will help you read it, but a single reading is noisy and different labs use different methods. Repeat it with the same test, at the same time of year, and look at the direction over several years. Short-term changes after one cycle should not be over-interpreted in either direction.
Why cycles instead of daily use? The research protocols that most Epithalon interest traces back to used short courses repeated at intervals, and continuous telomerase stimulation is exactly what the team wants to avoid given the cancer-biology question above. Short cycles also make the experience interpretable: there is a clear before, during and after, and a long gap in which nothing is being injected. If a patient asks for continuous use, the answer is no.
Combining Epithalon with other parts of a longevity plan is common, and the BHRC team keeps it deliberate. Adding several new compounds in the same month makes it impossible to tell what caused a side effect or a change in markers, so we stagger additions and change one variable at a time. Hormone therapy, NAD+, MOTS-c or a combined blend are each reviewed on their own merits, and none is added just because it is often stacked online. Where a single combined vial suits you better, our GHK/Epi/MOTS and GHK/Epithalon blend pages explain how those protocols differ.
Day-to-day monitoring is simple: injection-site reactions, any sleep change, and anything new or unusual reported between visits. Because the cycles are short, most of the safety picture is gathered at the end-of-cycle check and the annual review.
Dosing, reconstitution and cycling detail is covered in our Epithalon dosage guide. Your own plan is set by your provider at the consultation.
Regulatory status
Epithalon (epitalon) is not FDA-approved for longevity, anti-aging or any other use, and no FDA-approved product contains it. FDA previously placed epitalon in Category 2 of its 503A interim policy (substances that may present significant safety risks), citing immunogenicity concerns and a lack of safety information for the proposed route; the nomination was withdrawn by the nominator, and epitalon is not on the 503A bulks list. At BHRC it is prescribed only after a provider consultation, in short supervised cycles, with documented informed consent. Prepared by the BHRC team from FDA and PubMed sources.
Before you book
Epitalon and Epithalon are two spellings of the same synthetic tetrapeptide. Epithalamin is different: it is the older extract of animal pineal tissue that the synthetic peptide was modelled on, and much of the early human research used the extract rather than the synthetic peptide. That matters when you read claims online, because results for one are often quoted as if they applied to the other. BHRC protocols use the synthetic peptide only, from a licensed pharmacy.
It is used as an adjunct in longevity-focused plans by patients interested in telomere and pineal-rhythm research. It is not approved for any condition and is not a treatment for any disease.
The research describes telomerase activation and telomere lengthening in cultured human cells, changes in melatonin rhythm in small studies of older adults given the pineal extract, and lifespan effects in animals. None of these is proof of benefit for an individual patient, and the BHRC team presents them as research findings, not promised outcomes.
Your amount and cycle length are set by the clinical team at consultation. Published protocols and cycling patterns are covered in our Epitalon dosage and cycling guide, which is background reading rather than a prescription.
Reported effects are mostly minor injection-site reactions and occasional sleep changes, but the human safety data are limited, and FDA has said it has not identified safety-related information for the proposed route. Limited data is not the same as proven safety, which is why cycles are short and reviewed.
Partly. You can track markers over time, and you can buy a telomere-length test, but those tests are variable and no test can tell you that a specific cycle changed your health. The team helps you set up a consistent testing plan if you want one.
Vial strengths vary by pharmacy. The vial strength is a supply detail; the amount you inject and how long the cycle lasts are decided by the clinical team, and the pharmacy label is what your instructions are based on.
They target different parts of the ageing story: Epithalon is discussed for telomeres and pineal rhythm, NAD+ for cellular energy metabolism, and MOTS-c for mitochondrial and insulin signalling. None is approved for longevity. The right choice depends on your markers and goals, and many patients start with the one that matches a measurable target: an insulin-resistance pattern points toward a metabolic conversation, while someone with good metabolic markers who is interested in the telomere research may prefer a single yearly Epithalon cycle. The team will not stack all three by default.
Cost depends on the consultation, baseline labs, any optional telomere or biological-age test, the number of vials a cycle needs and the follow-up visits. Your BHRC centre provides an itemised quote at consultation; prices are not listed on this page.
Book a longevity consultation and bring recent labs and screening results if you have them. If anything preventive is overdue, that is arranged first; if you qualify, a cycle date is agreed and injection training is booked. Many patients time the cycle around a quieter part of the year so that the end-of-cycle check and the annual labs line up.
Selected research
The literature below is peer-reviewed background on Epithalon and the mechanisms discussed on this page, so you can read the primary sources yourself. It is not evidence of any particular outcome at BHRC, and some of it is preclinical work in animals or cells. Your provider will discuss what the evidence does and does not support for your situation.
Related peptide therapies
Peptide therapy
Triple-Action Longevity Formula
Questions
Epithalon is unique in its specific mechanism of action—telomerase activation. Unlike peptides that work on growth factors or metabolic pathways, Epithalon directly influences telomere length and cellular aging at the chromosomal level. It also regulates pineal gland function, supporting circadian rhythms and hormonal health. This dual action on cellular aging and biological rhythms makes it a cornerstone of evidence-based longevity protocols.
Epithalon is typically administered via subcutaneous injection. Standard protocols involve daily injections during treatment cycles lasting 10-20 days, followed by rest periods. Some protocols use longer cycles or maintenance dosing. Your physician will determine the optimal protocol based on your health status, goals, and response to therapy.
Results vary by individual, but many patients report improvements in sleep quality, energy levels, skin appearance, and overall vitality within the first treatment cycle. Cellular benefits including telomere maintenance occur at the molecular level and may not produce immediate subjective effects. Long-term effects on healthspan and biological age are still being studied. Consistency across multiple cycles and integration with comprehensive longevity protocols yield the best outcomes.
Epithalon is typically administered in cycles—10-20 days of daily injections followed by rest periods of several weeks to months. Many longevity-focused patients repeat cycles 2-4 times per year as part of a comprehensive healthspan optimization program. Because telomere shortening is ongoing, periodic treatment helps maintain telomere health over time. Your physician will design a cyclical protocol tailored to your age, health status, and longevity objectives.
Reported side effects in research are generally minor, but FDA notes it has not identified safety information for the proposed route. Some patients experience mild injection site reactions or transient changes in sleep patterns as circadian rhythms adjust. Serious adverse effects have rarely been reported, but data are limited. Because Epithalon influences cellular processes, medical supervision is essential to ensure appropriate use and monitor for any individual sensitivities.
Ideal candidates include adults interested in evidence-based longevity interventions, individuals seeking to optimize healthspan and biological age, and those committed to comprehensive preventive health strategies. Epithalon is generally well-suited for patients 35+ focusing on aging modulation, though younger patients may benefit in specific contexts. A physician consultation is required to determine if Epithalon aligns with your health profile and goals.
Epithalon may be discussed alongside other longevity approaches, including other peptides, hormone optimization, NAD+ therapy, senolytics, and lifestyle interventions. Many patients combine Epithalon with complementary peptides and metabolic therapies, although these combinations have not been studied. Your physician will review any combination and how it is monitored.
Get Started
Schedule a consultation with our medical team to learn if Epithalon telomerase activation therapy is right for your healthspan and longevity goals.
"*" indicates required fields
Or call us directly: +1 213-325-3373
*These statements have not been evaluated by the Food and Drug Administration. Epithalon is not FDA-approved for longevity or anti-aging purposes. Use is off-label and administered under medical supervision for research and therapeutic purposes. Results vary by individual based on age, genetics, baseline health, and treatment adherence. This peptide is intended for use only under qualified medical supervision. A consultation with our medical team is required to determine if this therapy is appropriate for you.
